CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...

FORE Biotherapeutics highlights pipeline achievements for its oncology programme; Provides objectives for 2025: Philadelphia Saturday, January 11, 2025, 17:00 Hrs [IST] FORE Bioth ...